These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32291887)

  • 1. Clinical efficacy and safety of certolizumab pegol in cutaneous symptoms on psoriasis in patients with psoriatic arthritis: A retrospective analysis in real life.
    Dattola A; Mazzeo M; Di Stefano F; Manfreda V; Vollono L; Di Raimondo C; Di Matteo E; Bianchi L
    Dermatol Ther; 2020 May; 33(3):e13409. PubMed ID: 32291887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis.
    Carubbi F; Fidanza R; Palmieri M; Ventura A; Tambone S; Cipriani P; Giacomelli R; Fargnoli MC
    J Dermatolog Treat; 2020 Nov; 31(7):692-697. PubMed ID: 30963798
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of certolizumab pegol in naïve versus multi-treated patients affected by psoriatic arthritis.
    Dattola A; Vollono L; Cannizzaro MV; Caposiena Caro RD; Mazzilli S; Melino G; Candi E; Campione E; Bianchi L
    Ital J Dermatol Venerol; 2021 Aug; 156(4):434-439. PubMed ID: 33034437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data.
    Dattola A; Cannizzaro MV; Mazzeo M; Bianchi L
    Dermatol Ther (Heidelb); 2017 Dec; 7(4):485-492. PubMed ID: 29139035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.
    Curtis JR; Mariette X; Gaujoux-Viala C; Blauvelt A; Kvien TK; Sandborn WJ; Winthrop K; de Longueville M; Huybrechts I; Bykerk VP
    RMD Open; 2019; 5(1):e000942. PubMed ID: 31245056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Certolizumab pegol in the treatment of psoriasis: Real-life data.
    Turkmen M; Dogan S
    Dermatol Ther; 2021 May; 34(3):e14929. PubMed ID: 33665940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
    Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ
    Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profile of certolizumab and its potential in the treatment of psoriatic arthritis.
    Chimenti MS; Saraceno R; Chiricozzi A; Giunta A; Chimenti S; Perricone R
    Drug Des Devel Ther; 2013; 7():339-48. PubMed ID: 23620660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol.
    Walsh JA; Arledge T; Nurminen T; Peterson L; Stark J
    J Rheumatol; 2018 Jul; 45(7):922-928. PubMed ID: 29717036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers.
    Vender RB; Lynde CW
    J Cutan Med Surg; 2022; 26(3):267-273. PubMed ID: 35134313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
    Mease PJ; Fleischmann R; Deodhar AA; Wollenhaupt J; Khraishi M; Kielar D; Woltering F; Stach C; Hoepken B; Arledge T; van der Heijde D
    Ann Rheum Dis; 2014 Jan; 73(1):48-55. PubMed ID: 23942868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
    Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
    J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis.
    Esposito M; Carubbi F; Giunta A; Alunno A; Giacomelli R; Fargnoli MC
    Expert Rev Clin Immunol; 2020 Feb; 16(2):119-128. PubMed ID: 31917928
    [No Abstract]   [Full Text] [Related]  

  • 15. Certolizumab pegol for the treatment of psoriasis.
    Campanati A; Benfaremo D; Luchetti MM; Ganzetti G; Gabrielli A; Offidani A
    Expert Opin Biol Ther; 2017 Mar; 17(3):387-394. PubMed ID: 28165828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial.
    Warren RB; Lebwohl M; Sofen H; Piguet V; Augustin M; Brock F; C Arendt ; Fierens F; Blauvelt A
    J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2398-2408. PubMed ID: 34192387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoriasiform skin eruption in a patient receiving certolizumab-pegol for ankylosing spondylitis: Report of a case and review of the literature.
    Babuna Kobaner G; Polat Ekinci A; Yilmaz Z; Copur S
    Dermatol Ther; 2018 Sep; 31(5):e12693. PubMed ID: 30225952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
    Glatt S; Taylor PC; McInnes IB; Schett G; Landewé R; Baeten D; Ionescu L; Strimenopoulou F; Watling MIL; Shaw S
    Ann Rheum Dis; 2019 Aug; 78(8):1033-1040. PubMed ID: 31177099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
    Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
    Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.